Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 17/20 | 1.00 |
| ▸ | CYSLTR1 | Q9Y271 | 17/20 | 1.00 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-648051 SCHEMBL30997207 | 0.99 | CYSLTR2 (0.98) | CYSLTR2CYSLTR1GRM2LMNACYP1A2 | |
| SCHEMBL9734027 | 0.95 | CYSLTR2 (0.91) | CYSLTR2CYSLTR1GRM2LMNACYP1A2 | |
| SCHEMBL10920237 | 0.92 | CYSLTR2 (0.84) | CYSLTR2CYSLTR1GRM2LMNACYP1A2 | |
| SCHEMBL9734285 | 0.91 | CYSLTR2 (0.83) | CYSLTR2CYSLTR1GRM2LMNACYP1A2 | |
| SCHEMBL11073016 | 0.89 | CYSLTR2 (0.80) | CYSLTR2CYSLTR1GRM2LMNACYP1A2 | |
| SCHEMBL9738293 | 0.88 | CYSLTR2 (0.79) | CYSLTR2CYSLTR1GRM2LMNACYP1A2 | |
| SCHEMBL9733407 | 0.88 | CYSLTR2 (0.79) | CYSLTR2CYSLTR1GRM2LMNACYP1A2 | |
| SCHEMBL9733844 | 0.88 | CYSLTR2 (0.79) | CYSLTR2CYSLTR1GRM2LMNACYP1A2 | |
| SCHEMBL9735766 | 0.87 | CYSLTR2 (0.77) | CYSLTR2CYSLTR1GRM2LMNACYP1A2 | |
| SCHEMBL9733439 | 0.87 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1GRM2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | claimed |
| EP-2849738-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2015-03-25 | — | — | EP | claimed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | claimed |
| WO-2013170655-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2013-11-21 | — | — | WO | claimed |
| EP-0104885-B1 | LEUKOTRIENE ANTAGONISTS, THEIR PRODUCTION, AND COMPOSITIONS CONTAINING THEM | MERCK FROSST CANADA INC. (CA) | 1986-06-04 | — | — | EP | claimed |
| US-20250092042-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| EP-4466251-A1 | TREATMENT OF SIGNS, SYMPTOMS AND/OR COMPLICATIONS OF VIRAL, BACTERIAL, PROTOZOAL, AND/OR FUNGAL INFECTIONS BY HIGH PENETRATION PRODRUGS | TECHFIELDS INC. (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-118556043-A | Treatment of signs, symptoms and/or complications of viral, bacterial, protozoal and/or fungal infections by highly penetrating prodrugs | 苏州泰飞尔医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| EP-4356912-A2 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2024-04-24 | — | — | EP | disclosed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| US-5135940-A | Antiallegens, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1992-08-04 | — | — | US | disclosed |
| US-4876246-A | Benzo[a]phenothiazines and hydro-derivatives for inhibiting leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1989-10-24 | — | — | US | disclosed |
| EP-0252639-A1 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1988-01-13 | — | — | EP | disclosed |
| EP-0104885-B1 | LEUKOTRIENE ANTAGONISTS, THEIR PRODUCTION, AND COMPOSITIONS CONTAINING THEM | MERCK FROSST CANADA INC. (CA) | 1986-06-04 | — | — | EP | disclosed |
| EP-0156233-A2 | Use of leukotriene antagonists for producing cytoprotective pharmaceutical compositions and process for producing cytoprotective pharmaceutical compositions | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0104885-A1 | Leukotriene antagonists, their production, and compositions containing them | MERCK FROSST CANADA INC. (CA) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CYSLTR2 435/4885CYSLTR1 504/4885GRM2 2998/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CYSLTR2 435/4885CYSLTR1 504/4885GRM2 2998/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CYSLTR2 435/4885CYSLTR1 504/4885GRM2 2998/4885 |
| US-20250092042-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, PKD1, PKD2 | CYSLTR2 2928/4885CYSLTR1 2354/4885GRM2 3999/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CYSLTR2 435/4885CYSLTR1 504/4885GRM2 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.